Top

Published in:

Open Access 01-12-2024 | Triptan Drugs | Research

Triptan use in elderly over 65 years and the risk of hospitalization for serious vascular events

Authors: Phuong Thao Tran, Maryse Lapeyre-Mestre, Baricault Berangere, Michel Lanteri-Minet, Aurore Palmaro, Anne Donnet, Joëlle Micallef

Published in: The Journal of Headache and Pain | Issue 1/2024

Abstract

Background

Several studies have focused on the use of triptan and the risk of acute vascular events but the existence of such association is still debated and has never been quantified in patients over 65 years. To assess whether triptan use among older is associated with an increased risk of hospitalization for acute vascular events.

Methods

A propensity score-matched cohort study was designed using the French national health insurance database linked to hospital stays. Patients aged ≥ 65 years, newly treated by triptans between 2011 and 2014, were included… The primary event was hospitalization for an acute ischemic vascular event within de 90 days following triptan initiation. Association with triptan exposure was investigated through cox regression model, considering exposure at inclusion, and with exposure as a time-varying variable A case-crossover (CCO) and a self-controlled case series (SCCS) analyses were also conducted to address potential residual confounding.

Results

The cohort included 24, 774 triptan users and 99 096 propensity matched controls (mean (SD) age: 71 years (5.9), 74% of women). Within 90 days after cohort entry, 163 events were observed in the triptan group, and 523 in the control group (0.66% vs. 0.53%, adjusted hazard ratio (aHR) _{exposed/not exposed} 1.25 95%CI [1.05–1.49]; aHR _{time−varying} 8.74 [5.21–14.66]). The association was significant (CCO) for all events (adjusted odds ratio (aOR1.63 [1.22–2.19]) with a more consistent association with cerebral events (aOR 2.14 [1.26–3.63]). The relative incidence (RI) for all events was 2.13 [1.76–2.58] in the SCCS, for cardiac (RI: 1.67 [1.23–2.27]) and for cerebral events (RI: 3.20, [2.30–4.45]).

Conclusion

The incidence of acute vascular events was low among triptan users. We found that triptan use among older may be associated with a low increased risk for acute vascular events, which may be more marked for cerebral events such as stroke, than for cardiac events.

Available only for authorised users

Loder E (2010) Triptan therapy in migraine. N Engl J Med 363(1):63–70CrossRefPubMed

Ghanshani S, Chen C, Lin B, Duan L, Shen YA, Lee MS (2020) Risk of Acute Myocardial Infarction, Heart failure, and death in Migraine patients treated with triptans. Headache 60(10):2166–2175CrossRefPubMed

Hugger SS, Do TP, Ashina H, Goicochea MT, Jenkins B, Sacco S, Lee MJ, Brennan KC, Amin FM, Steiner TJ, Ashina M (2023) Migraine in older adults. Lancet Neurol 22(10):934–945CrossRefPubMed

Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, Loutfi H, Welch KM, Goadsby PJ, Hahn S, Hutchinson S, Matchar D, Silberstein S, Smith TR, Purdy RA, Saiers J (2004) Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44(5):414–425CrossRefPubMed

Hall GC, Brown MM, Mo J, MacRae KD (2004) Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 62(4):563–568CrossRefPubMed

Lugardon S, Roussel H, Sciortino V, Montastruc JL, Lapeyre-Mestre M (2007) Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database. Eur J Clin Pharmacol 63(8):801–807CrossRefPubMed

Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM (2004) Severe vascular events in migraine patients. Headache 44(7):642–651CrossRefPubMed

Wammes-van der Heijden EA, Rahimtoola H, Leufkens HGM, Tijssen CC, Egberts ACG (2006) Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology 67(7):1128–1134CrossRefPubMed

Zebenholzer K, Gall W, Gleiss A, Pavelic AR, Wöber C (2022) Triptans and vascular comorbidity in persons over fifty: findings from a nationwide insurance database - A cohort study. Headache 62(5):604–612CrossRefPubMedPubMedCentral

10.

Dekker F, Wiendels NJ, de Valk V et al (2011) Triptan overuse in the Dutch general population: nationwide pharmaco-epidemiology database analysis in 6.7 million people. Cephalalgia 31(8):943–952. https://doi.org/10.1177/0333102411408626CrossRefPubMed

11.

Braunstein D, Donnet A, Pradel V et al (2015) Triptans use and overuse: a pharmacoepidemiology study from the French health insurance system database covering 4.1 million people. Cephalalgia 35(13):1172–1180. https://doi.org/10.1177/0333102415570497CrossRefPubMed

12.

Panconesi A, Pavone E, Vacca F, Vaiani M, Banfi R (2008) Triptans in the Italian population: a drug utilization study and a literature review. J Headache Pain 9(2):71–76. https://doi.org/10.1007/s10194-008-0020-3CrossRefPubMedPubMedCentral

13.

Biagi C, Poluzzi E, Roberto G, Puccini A, Vaccheri A, D’Alessandro R, Motola D, Montanaro N (2011) Pattern of triptan use and cardiovascular coprescription: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol 67(12):1283–1289CrossRefPubMed

14.

Tuppin P, Rudant J, Constantinou P et al (2017) Value of a national administrative database to guide public decisions: from the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique 65(Suppl 4):S149–S167. https://doi.org/10.1016/j.respe.2017.05.004CrossRefPubMed

15.

Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc J-L, Sailler L (2015) French health insurance databases: what interest for medical research? Rev Med Interne 36(6):411–417. https://doi.org/10.1016/j.revmed.2014.11.009CrossRefPubMed

16.

Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M (2016) Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fundam Clin Pharmacol 30(6):616–624. https://doi.org/10.1111/fcp.12214CrossRefPubMed

17.

Tuppin P, Samson S, Woimant F, Chabrier S (2014) Management and 2-year follow-up of children aged 29 days to 17 years hospitalized for a first stroke in France (2009–2010). Arch Pediatr 21(12):1305–1315. https://doi.org/10.1016/j.arcped.2014.08.023CrossRefPubMed

18.

Danchin N, Neumann A, Tuppin P et al (2011) Impact of free universal medical coverage on medical care and outcomes in low-income patients hospitalized for acute myocardial infarction: an analysis from the FrenchNational Health Insurance system. Circ Cardiovasc Qual Outcomes 4(6):619–625. https://doi.org/10.1161/CIRCOUTCOMES.111.961193CrossRefPubMed

19.

Bezin J, Girodet P-O, Rambelomanana S et al (2015) Choice of ICD-10 codes for the identification of acute coronary syndrome in the French hospitalization database. Fundam Clin Pharmacol 29(6):586–591. https://doi.org/10.1111/fcp.12143

20.

Neumann A, Maura G, Weill A, Ricordeau P, Alla F, Allemand H (2014) Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. Pharmacoepidemiol Drug Saf 23(3):240–250. https://doi.org/10.1002/pds.3544CrossRefPubMed

21.

Maclure M (1991) The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 133(2):144–153. https://doi.org/10.1093/oxfordjournals.aje.a115853CrossRefPubMed

22.

Gault N, Castañeda-Sanabria J, De Rycke Y, Guillo S, Foulon S, Tubach F (2017) Self-controlled designs in pharmacoepidemiology involving electronic healthcare databases: a systematic review. BMC Med Res Methodol 17(1):25CrossRefPubMedPubMedCentral

23.

Farrington P, Pugh S, Colville A, Flower A, Nash J, Morgan-Capner P, Rush M, Miller E (1995) A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 345(8949):567–569CrossRefPubMed

24.

Lafaurie M, Lapeyre-Mestre M, Sailler L, Sommet A, Moulis G (2022) Risk of Immune Thrombocytopenia after Influenza Vaccine. JAMA Intern Med 182(4):444–445CrossRefPubMedPubMedCentral

25.

Bannay A, Chaignot C, Blotière P-O et al (2016) The best use of the Charlson Comorbidity Index with Electronic Health Care Database to Predict Mortality. Med Care 54(2):188–194. https://doi.org/10.1097/MLR.0000000000000471CrossRefPubMed

26.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8CrossRefPubMed

27.

Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA (2004) New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 57(12):1288–1294. https://doi.org/10.1016/j.jclinepi.2004.03.012

28.

Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130–1139. https://doi.org/10.1097/01.mlr.0000182534.19832.83CrossRefPubMed

29.

WHO Collaborating Centre for Drug Statistics Methodology (2021) ATC Classification Index with DDDs, 2021. Oslo, Norway 2020. https://www.Whocc.No/Atc_ddd_index/

30.

Prat M, Derumeaux H, Sailler L, Lapeyre-Mestre M, Moulis G (2018) Positive predictive values of peripheral arterial and venous thrombosis codes in French hospital database. Fundam Clin Pharmacol 32(1):108–113CrossRefPubMed

31.

Albieri V, Olsen TS, Andersen KK (2016) Risk of Stroke in migraineurs using triptans. Associations with Age, Sex, Stroke Severity and Subtype. EBioMedicine 6:199–205. https://doi.org/10.1016/j.ebiom.2016.02.039CrossRefPubMedPubMedCentral

32.

33.

Roberto G, Piccinni C, D’Alessandro R, Poluzzi E (2014) Triptans and serious adverse vascular events: data mining of the FDA adverse event reporting System database. Cephalalgia 34(1):5–13. https://doi.org/10.1177/0333102413499649CrossRefPubMed

34.

Petersen CL, Hougaard A, Gaist D, Hallas J (2024 Feb) Risk of stroke and myocardial infarction among initiators of triptans. JAMA Neurol 5:e235549

36.

Donnet A, Emery C, Aly S et al (2019) Migraine burden and costs in France: a nationwide claims database analysis of triptan users. J Med Econ 22(7):616–624. https://doi.org/10.1080/13696998.2019.1590841CrossRefPubMed

37.

Riggins N, Ehrlich A (2022) Episodic migraine and older adults. Curr Pain Headache Rep 26(4):331–335CrossRefPubMedPubMedCentral

38.

Kalkman DN, Couturier EGM, El Bouziani A, Dahdal J, Neefs J, Woudstra J, Vogel B, Trabattoni D, MaassenVanDenBrink A, Mehran R, de Winter RJ, Appelman Y (2023) Migraine and cardiovascular disease: what cardiologists should know. Eur Heart J 44(30):2815–2828CrossRefPubMed

39.

Ng CYH, Tan BYQ, Teo YN, Teo YH, Syn NLX, Leow AST, Ho JSY, Chan MY, Wong RCC, Chai P, Chan ACY, Sharma VK, Yeo LLL, Sia CH, Ong JJY (2022) Myocardial infarction, stroke and cardiovascular mortality among migraine patients: a systematic review and meta-analysis. J Neurol 269(5):2346–2358CrossRefPubMed

40.

Bigal ME, Golden W, Buse D, Chen Y-T, Lipton RB (2010) Triptan use as a function of cardiovascular risk. A population-based study. Headache 50(2):256–263. https://doi.org/10.1111/j.1526-4610.2009.01595.xCrossRefPubMed

41.

Dodick D, Lipton RB, Martin V et al (2004) Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44(5):414–425. https://doi.org/10.1111/j.1526-4610.2004.04078.xCrossRefPubMed

42.

MacClellan LR, Giles W, Cole J et al (2007) Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke 38(9):2438–2445. https://doi.org/10.1161/STROKEAHA.107.488395CrossRefPubMed

43.

Kurth T, Chabriat H, Bousser M-G (2012) Migraine and stroke: a complex association with clinical implications. Lancet Neurol 11(1):92–100. https://doi.org/10.1016/S1474-4422(11)70266-6

44.

Gudmundsson LS, Scher AI, Aspelund T et al (2010) Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study. BMJ 341:c3966. https://doi.org/10.1136/bmj.c3966CrossRefPubMedPubMedCentral

45.

de Hoon JN, Willigers JM, Troost J, Struijker-Boudier HA, Van Bortel LM (2000) Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther 68(4):418–426. https://doi.org/10.1067/mcp.2000.110502CrossRefPubMed

46.

Van Den Maassen A, Saxena PR (2004) Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. Headache 44(Suppl 1):S13–19. https://doi.org/10.1111/j.1526-4610.2004.04104.xCrossRef

47.

Lorgis L, Gudjoncik A, Richard C et al (2012) Pre-infarction angina and outcomes in non-ST-segment elevation myocardial infarction: data from the RICO survey. PLoS ONE 7(12):e48513. https://doi.org/10.1371/journal.pone.0048513CrossRefPubMedPubMedCentral

48.

Li L, Setoguchi S, Cabral H, Jick S (2013) Opioid use for noncancer pain and risk of myocardial infarction amongst adults. J Intern Med 273(5):511–526. https://doi.org/10.1111/joim.12035CrossRefPubMed

49.

Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2016) Prescription of long-acting opioids and mortality in patients with chronic Noncancer Pain. JAMA 315(22):2415–2423. https://doi.org/10.1001/jama.2016.7789CrossRefPubMedPubMedCentral

50.

Onan D, Wells-Gatnik WD, Bentivegna E, Lampl C, Martelletti P (2023) New Migraine drugs for older adults. Drugs Aging 40(4):301–305CrossRefPubMed

Title: Triptan use in elderly over 65 years and the risk of hospitalization for serious vascular events
Authors: Phuong Thao Tran
Maryse Lapeyre-Mestre
Baricault Berangere
Michel Lanteri-Minet
Aurore Palmaro
Anne Donnet
Joëlle Micallef
Publication date: 01-12-2024
Publisher: Springer Milan
Keywords: Triptan Drugs
Stroke
Myocardial Infarction
Migraine
Published in: The Journal of Headache and Pain / Issue 1/2024
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-024-01770-x

At a glance: The STEP trials

Springer Medicine

Triptan use in elderly over 65 years and the risk of hospitalization for serious vascular events

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society

Environmental enrichment alleviates hyperalgesia by modulating central sensitization in a nitroglycerin-induced chronic migraine model of mice

CGRP-targeted medication in chronic migraine - systematic review

Reconceptualizing autonomic function testing in migraine: a systematic review and meta-analysis

Dynamic changes in glymphatic function in reversible cerebral vasoconstriction syndrome

Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study